-
Basel, June 11, 2021 — Novartis today announced new Phase II data for iptacopan (LNP023), an investigational oral treatment for paroxysmal nocturnal hemoglobinuria (PNH), presented at the 26th Annual Congress of the European Hematology Association (EHA). In the study (NCT03896152), treatment with 12 weeks of iptacopan monotherapy was generally…Reimagine MedicineMedical InnovationsClinical Science
-
A Novartis team couriers an experimental treatment across Europe to a patient as transit grinds to a halt.
COVID-19DigitalClinical ResearchClinical TrialsClinical ScienceDrug Development -
Chinweike Ukomadu thinks that notions about clinicians turning their backs on patients when transitioning to industry are outdated.
Novartis Institutes for BioMedical ResearchClinical ResearchCareersClinical TrialsClinical Science -
OncologyWomen in ScienceWorking at NovartisCareersClinical Science
-
Meet a Senior Medical Director at Novartis who is part of our new “Women in Science” series
OncologyWorking at NovartisCareersClinical Science -
Biomedical ResearchDrug DiscoveryNovartis Institutes for BioMedical ResearchClinical ScienceCancer Research Institute
-
A reversal in thinking about the reversibility of liver damage is changing the field of hepatology.
Biomedical ResearchNovartis Institutes for BioMedical ResearchClinical ScienceDrug Design